Pluri Inc
PLUR.TA
ILA1 059.00 -3.20%
Exchange: TLV | Sector: Healthcare | Industry: Biotechnology
Q4 2024
Published: Sep 18, 2024

Earnings Highlights

  • Revenue of $0.10M down 13.5% year-over-year
  • EPS of $-1.06 increased by 15.2% from previous year
  • Gross margin of 32.3%
  • Net income of -5.73M
  • "N/A" - N/A
PLUR.TA
Company PLUR.TA

Executive Summary

Pluri Inc reported QQ4 2024 results with very modest revenue of $96 thousand against a substantial operating burn driven by R&D and general & administrative expenses. The quarter shows a sharp contrast between a positive gross profit of $31 thousand on $96 thousand of revenue (gross margin ~32%), and an overall EBITDA of negative $5.58 million with an operating loss of $6.03 million. Net loss for the quarter was $5.73 million, translating to a negative basic EPS of $1.06. Cash burn from operations was $4.31 million, contributing to a reduction in liquidity despite a financing inflow that lifted net cash provided by financing activities to $8.84 million. End-of-period cash and equivalents stood at $7.67 million, while total debt remained high at approximately $29.6 million, with long-term debt around $29.05 million. The balance sheet reflects a heavily leveraged and still-loss-making biotechnology company, including a large accumulated deficit (~$420.5 million) and a near-zero equity base. Net debt stood at about $22.83 million, underscoring an equity/debt balance that requires external funding or milestone-driven collaborations for runway extension. The companyโ€™s pipeline is anchored by PLXPAD (placental expanded cell therapy) with Phase III trials for hip fracture recovery and GVHD, in addition to PLXR18 and other initiatives; management commentary typically centers on advancing these assets and pursuing partnerships, though no transcript data was provided for direct quotes in this dataset. In summary, the QQ4 2024 quarter reinforces Pluriโ€™s position as a late-stage research-focused biotech with high long-run upside contingent on successful trial milestones and strategic financing, yet facing material near-term liquidity and profitability risks.

Key Performance Indicators

Revenue
Decreasing
96.00K
QoQ: 35.21% | YoY: -13.51%
Gross Profit
Decreasing
31.00K
32.29% margin
QoQ: 210.00% | YoY: -99.53%
Operating Income
Increasing
-6.03M
QoQ: -9.04% | YoY: 7.79%
Net Income
Increasing
-5.73M
QoQ: -8.24% | YoY: 11.30%
EPS
Increasing
-1.06
QoQ: -4.95% | YoY: 15.20%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 0.43 -0.94 +501.4% View
Q2 2025 0.19 -0.53 +76.2% View
Q1 2025 0.33 -1.12 +503.7% View
Q4 2024 0.10 -1.06 -13.5% View
Q3 2024 0.07 -1.01 -18.4% View